KR20190005871A - 안정한 니모디핀 비경구 제제 - Google Patents

안정한 니모디핀 비경구 제제 Download PDF

Info

Publication number
KR20190005871A
KR20190005871A KR1020187032646A KR20187032646A KR20190005871A KR 20190005871 A KR20190005871 A KR 20190005871A KR 1020187032646 A KR1020187032646 A KR 1020187032646A KR 20187032646 A KR20187032646 A KR 20187032646A KR 20190005871 A KR20190005871 A KR 20190005871A
Authority
KR
South Korea
Prior art keywords
nimodipine
formulation
injection
concentrate
pharmaceutically acceptable
Prior art date
Application number
KR1020187032646A
Other languages
English (en)
Korean (ko)
Inventor
에스. 조지 코테일
암레쉬 쿠마르
프라잔나 순탄카르
비말 카부루
Original Assignee
노틱 홀딩스 잉크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노틱 홀딩스 잉크. filed Critical 노틱 홀딩스 잉크.
Publication of KR20190005871A publication Critical patent/KR20190005871A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187032646A 2016-04-13 2017-04-12 안정한 니모디핀 비경구 제제 KR20190005871A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322008P 2016-04-13 2016-04-13
US62/322,008 2016-04-13
PCT/US2017/027164 WO2017180718A1 (en) 2016-04-13 2017-04-12 Stable nimopidine parenteral formulation

Publications (1)

Publication Number Publication Date
KR20190005871A true KR20190005871A (ko) 2019-01-16

Family

ID=60039305

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032646A KR20190005871A (ko) 2016-04-13 2017-04-12 안정한 니모디핀 비경구 제제

Country Status (18)

Country Link
US (3) US10092557B2 (de)
EP (2) EP4032527A1 (de)
JP (3) JP2019511522A (de)
KR (1) KR20190005871A (de)
CN (2) CN109069651A (de)
AU (2) AU2017249396A1 (de)
BR (1) BR112018070960A2 (de)
CA (1) CA3021237A1 (de)
DK (1) DK3442586T3 (de)
EA (1) EA201891977A1 (de)
ES (1) ES2927490T3 (de)
HR (1) HRP20221100T1 (de)
HU (1) HUE059921T2 (de)
IL (1) IL262335A (de)
PL (1) PL3442586T3 (de)
PT (1) PT3442586T (de)
SI (1) SI3442586T1 (de)
WO (1) WO2017180718A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023140582A1 (ko) * 2022-01-24 2023-07-27 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132728A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for the treatment of demyelinating conditions
US11517563B2 (en) 2018-01-25 2022-12-06 Azurity Pharmaceuticals, Inc. Liquid nimodipine compositions
US10342787B1 (en) * 2018-01-25 2019-07-09 Arbor Pharmaceuticals, Llc Non-aqueous liquid nimodipine compositions
WO2019165066A2 (en) 2018-02-22 2019-08-29 Nortic Holdings Inc. Stable nimodipine parenteral formulation
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
EP3848021A4 (de) * 2018-09-08 2023-11-29 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Nimodipininjektionszusammensetzung und herstellungsverfahren dafür
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US20240091147A1 (en) * 2019-11-25 2024-03-21 Fordoz Pharma Corp. Oral liquid formulations of lipid-lowering and blood pressure-lowering drugs
CN112137956A (zh) * 2020-10-26 2020-12-29 辰欣药业股份有限公司 一种尼莫地平缓释乳注射液的制备方法
CN113509434A (zh) * 2021-04-26 2021-10-19 广东金城金素制药有限公司 尼莫地平口服溶液、其制备方法和应用
WO2023224851A1 (en) * 2022-05-16 2023-11-23 Acasti Pharma U.S., Inc. Nimodipine parenteral administration
CN115990262A (zh) * 2022-06-27 2023-04-21 北京德立福瑞医药科技有限公司 不含乙醇和磷脂的湿热灭菌的尼莫地平组合物及其制备方法
CN116350586B (zh) * 2023-04-19 2024-02-20 山东泰合医药科技有限公司 一种尼莫地平胶束注射液及其制备方法
CN116898801B (zh) * 2023-06-20 2024-08-16 济南大学 一种尼莫地平胶束组合物制备方法及其产品

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3316510A1 (de) 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4879308A (en) 1987-08-11 1989-11-07 Lyphomed, Inc. Aqueous nitroglycerin injection and manufacturing process
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6363471B1 (en) 2000-01-03 2002-03-26 Advanced Micro Devices, Inc. Mechanism for handling 16-bit addressing in a processor
JP2005503446A (ja) 2001-01-11 2005-02-03 イーストマン ケミカル カンパニー シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
DE10124952A1 (de) * 2001-05-21 2002-12-12 Bayer Ag Verfahren zur Herstellung von Nanodispersionen
US6566347B1 (en) 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CN1183908C (zh) * 2003-08-08 2005-01-12 北京四环科宝制药有限公司 一种尼莫地平的注射用药物组合物及其制备方法
CN1589795A (zh) * 2003-09-04 2005-03-09 范敏华 尼莫地平冻干组合物及其制备方法
EP1933837A4 (de) * 2005-10-14 2009-07-15 Transform Pharmaceuticals Inc Pharmazeutische flüssigkeitszusammensetzungen aus nimodipin
CN101129366A (zh) * 2007-08-23 2008-02-27 沈阳万爱普利德医药科技有限公司 一种尼莫地平药物组合物及其制备方法
US7947293B2 (en) 2008-04-08 2011-05-24 Arpida Ag Aqueous pharmaceutical formulation
CN101904814A (zh) * 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102525917B (zh) * 2012-01-04 2014-06-18 四川百利药业有限责任公司 一种尼莫地平胶束注射剂及其制备方法
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023140582A1 (ko) * 2022-01-24 2023-07-27 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제

Also Published As

Publication number Publication date
HRP20221100T1 (hr) 2022-11-25
US10765671B2 (en) 2020-09-08
EP3442586A1 (de) 2019-02-20
CN114886850A (zh) 2022-08-12
SI3442586T1 (sl) 2023-01-31
WO2017180718A1 (en) 2017-10-19
AU2020201863A1 (en) 2020-04-02
JP2019511522A (ja) 2019-04-25
EA201891977A1 (ru) 2019-09-30
JP7196373B2 (ja) 2022-12-27
EP3442586B1 (de) 2022-06-08
EP3442586A4 (de) 2019-11-20
US11433062B2 (en) 2022-09-06
PT3442586T (pt) 2022-09-28
CN109069651A (zh) 2018-12-21
US20180325886A1 (en) 2018-11-15
EP4032527A1 (de) 2022-07-27
HUE059921T2 (hu) 2023-01-28
JP2022009013A (ja) 2022-01-14
US20200397773A1 (en) 2020-12-24
ES2927490T3 (es) 2022-11-07
JP2021011488A (ja) 2021-02-04
AU2017249396A1 (en) 2018-10-18
CA3021237A1 (en) 2017-10-19
PL3442586T3 (pl) 2023-01-30
US10092557B2 (en) 2018-10-09
US20170296527A1 (en) 2017-10-19
IL262335A (en) 2018-11-29
AU2020201863B2 (en) 2022-04-28
BR112018070960A2 (pt) 2019-01-29
DK3442586T3 (da) 2022-09-12

Similar Documents

Publication Publication Date Title
JP7196373B2 (ja) 安定なニモジピン非経口製剤
RU2642234C2 (ru) Композиции антагонистов нейрокинина-1 для внутривенного введения
US10799486B2 (en) Stable nimodipine parenteral formulation
US12059415B2 (en) Stable nimodipine parenteral formulation
US9241922B2 (en) Pharmaceutical solution of taxanes comprising pH regulator and preparation method thereof
US20200397769A1 (en) Stable nimodipine parenteral formulation
US20200163947A1 (en) Methods of treatment using nimodipine parenteral formulations
US20230364068A1 (en) Nimodipine Parenteral Administration
CN113613632A (zh) 麻醉剂的稳定制剂和相关剂型
WO2019006134A1 (en) STABLE PARENTERAL FORMULATION OF NIMODIPINE
US20240350473A1 (en) Stable nimodipine parenteral formulation
WO2012156999A1 (en) Ready to use docetaxel formulation

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X601 Decision of rejection after re-examination